Benchmark analyst Bill Sutherland downgraded Amedisys (AMED) to Hold from Buy after the company accepted UnitedHealth’s (UNH) Optum’s all-cash offer to be acquired for $101 per share, which was sweetened by 1% from the original offer in May, and Option Care Health (OPCH) announced that it had terminated its agreement to combine with Amedisys. The firm is lower its rating to Hold, acknowledging the current arbitrage opportunity given the $101 per share take-out price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMED:
- Amedisys price target raised to $101 from $97 at Truist
- Amedisys price target raised to $101 from $88 at Barclays
- UNH Gains Slightly after Announcing New Merger Deal
- Option Care Health confirms termination of merger agreement with Amedisys
- Amedisys to combine with Optum in all-cash deal at $101 per share